Skip to search formSkip to main contentSkip to account menu

SAR245408

Known as: SAR 245408 
National Institutes of Health

Related topics

Related topics

1 relation
XL147

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2016
2016
Phase I safety and pharmacokinetic dose-escalation study of pilaralisib polymorph E, a phosphoinositide 3-kinase inhibitor in tablet formulation, in patients with solid tumors or lymphoma
PurposePilaralisib (SAR245408), a pan-class I PI3K inhibitor, has been investigated in Phase I/II trials in several solid tumors… 
2015
2015
Biomarcadores farmacodinámicos y predictivos de respuesta en la toma de decisiones en ensayos clínicos Fase I de terapias dirigidas contra el cáncer
Este trabajo se centra en el papel de los biomarcadores en el desarrollo temprano de farmacos en Oncologia, e introduce un… 
2015
2015
Phase I safety and pharmacokinetic (PK) dose escalation study with SAR245408 (S) polymorph E, a PI3K inhibitor, in patients (pts) with solid tumors or lymphoma.
e13599 Background: S is a potent and selective inhibitor of PI3K class I isoforms. PI3K is implicated in tumor cell proliferation… 
2015
2015
Correction: Phase I Safety, Pharmacokinetic, and Pharmacodynamic Study of SAR245408 (XL147), an Oral Pan-Class I PI3K Inhibitor, in Patients with Advanced Solid Tumors
2011
2011
P1-17-02: A Phase 1/2 Study of SAR245408 (S08) in Combination with Trastuzumab (T) or Paclitaxel (P) and T in Patients with HER2+ Metastatic Breast Cancer (MBC) Who Progressed on a Previous T-Based…
BACKGROUND: Most HER2+ MBC patients (pts) treated with a combination of T+P progress within 1 year. Activation of downstream… 
2011
2011
Abstract LB-295: Combination of PI3K (SAR245408 and SAR245409) and MEK (MSC1936369B) inhibitors induce tumor apoptosis in vivo: fluorescence molecular tomography study in a human colon carcinoma…
The Merck-Serono MEK1/2 allosteric inhibitor MSC1936369B (formerly known as AS703026) was combined with the sanofi-aventis pan… 
2011
2011
P1-17-09: A Phase 1/2 Dose-Escalation Study of SAR245408 (S08) or SAR245409 (S09) in Combination with Letrozole (L) in Subjects with Hormone Receptor-Positive and HER2−Negative (HR+/HER2−) Breast…
Background: Upregulation of PI3K activity is a common molecular mechanism involved in resistance to AIs. S08 is a potent, orally… 
2011
2011
Abstract LB-208: Hijacking the PI3K/mTor and KRas/MEK/ERK signaling pathways with a therapeutic assault results in robust antitumor activity in PI3K/KRas and KRas mutant tumors
The PI3K/AKT/mTOR and Ras/Raf/MEK/ERK are interlinked growth and survival signaling pathways both involving regulation by Ras and… 
2010
2010
A phase I safety and pharmacokinetic (PK) study of the PI3K inhibitor XL147 (SAR245408) in combination with paclitaxel (P) and carboplatin (C) in patients (pts) with advanced solid tumors.
3078 Background: Upregulation of PI3K pathway signaling is associated with tumor resistance to P and C. The oral selective Class… 
2010
2010
A phase I safety and pharmacokinetic (PK) study of the PI3K inhibitor XL147 (SAR245408) in combination with erlotinib in patients (pts) with advanced solid tumors.
3070 Background: The PI3K pathway is frequently dysregulated in cancer cells and has been implicated as a mechanism of resistance… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)